In February last year, the U.S. Food & Drug Administration (FDA) announced a pilot program to encourage new technologies to be trialed in the pharmaceutical supply chain. A blockchain consortium of IBM, KPMG, Merck and Walmart was formed as one of the pilot groups, and today detailed results were published.
In February last year, the U.S. Food & Drug Administration (FDA) announced a pilot program to encourage new technologies to be trialed in the pharmaceutical supply chain. A blockchain consortium of IBM, KPMG, Merck and Walmart was formed as one of the pilot groups, and today detailed results were published.
The FDA’s purpose was to ensure that companies are prepared for the Drug Supply Chain Security Act (DSCSA), which is being phased in gradually through to 2023. One of the stages that became law last year was to ensure that returns made to wholesalers can be verified as legitimate. As many returns are re-sold, this helps to ensure mainstream wholesalers do not inadvertently sell counterfeit drugs.
Article continues …
Want the full story? Pro subscribers get complete articles, exclusive industry analysis, and early access to legislative updates that keep you ahead of the competition. Join the professionals who are choosing deeper insights over surface level news.
